Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
In our study we aim to examine the effect of SSRI augmentation on negative symptoms and cognitive function in schizophrenia patients as well as to examine the effect of SSRI augmentation on the RNA and protein products in…
- Trial name
- NCT00645580
- Testing
- Fluvoxamine
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Schizophrenia
Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
- Trial name
- NCT02453893
- Testing
- Iloperidone, Risperidone
- Where
- China
- Volunteers
- 288 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Psychotic Disorders, Schizophrenia
Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) injection of 75 mg risperidone LAI in the…
- Trial name
- NCT00821600
- Testing
- risperidone IR and LAI formulation
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Cue-based Intervention in Prospective Memory and Medication Adherence.
Medication adherence is a major challenge while treating patients with major mental illnesses like schizophrenia and schizoaffective disorder.
- Trial name
- NCT06474195
- Testing
- Cue based intervention, Treatment as Usual
- Where
- India
- Volunteers
- 104 people
- Sponsor
- University of Pittsburgh
Schizophrenia; Negative Type
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Schizophrenia patients commonly present with persistent negative symptoms which remain the main reason for dysfunction after recovery from an acute episode of psychotic symptoms.
- Trial name
- NOBLE-TMS (NCT06351514)
- Testing
- Accelerated iTBS
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Institute of Mental Health, Singapore
Schizophrenia, Psychotic Disorders
A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
The primary purpose of the study is to assess the safety and tolerability of a long-acting injectable formulation of risperidone when switching from an oral antipsychotic in patients with schizophrenia.
- Trial name
- NCT00034775
- Testing
- risperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metabolic Disturbance, Schizophrenia
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Background and objective: Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances.
- Conditions
- Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine
- Trial name
- NCT04892199
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- 3 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Schizophrenia
Long-Term Exercise Training Therapy Versus Usual Care in Patients With Schizophrenia
Patients with schizophrenia have disabling symptoms and cognitive deficits that limit motivation, drive, social- and occupational performance, quality of life and self-efficacy.
- Trial name
- LEXUS (NCT02743143)
- Testing
- Exercise therapy, Follow-up care as usual
- Where
- Norway
- Volunteers
- 48 people
- Sponsor
- St. Olavs Hospital
Schizophrenia
A Long-term Trial of OPC-34712 in Patients With Schizophrenia
To investigate the safety and efficacy of long-term administration of OPC-34712 in patients with schizophrenia.
- Trial name
- NCT01456897
- Testing
- OPC-34712
- Where
- Japan
- Volunteers
- 282 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia Spectrum Disorders
OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia
The effectiveness of current treatment options for sociocognitive deficits and negative symptoms (NS) in schizophrenia spectrum disorders (SSD) remains limited.
- Trial name
- OXYMIND (NCT06136390)
- Testing
- Oxytocin
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia, Schizoaffective Disorder
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
The objective of the study is to evaluate the efficacy of Pramipexole, Minocycline and Aspirin compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia.
- Trial name
- MAP-S-01 (NCT01320982)
- Testing
- minocycline, pramipexole, acetylsalicylic acid
- Where
- 14 sites in Israel, Romania
- Volunteers
- 400 people
- Sponsor
- Sheba Medical Center
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
The purpose of this study is to compare the effectiveness and safety over 1 year of treatment of intramuscular injections of paliperidone palmitate and long-acting risperidone in patients with schizophrenia.
- Trial name
- NCT00210717
- Testing
- paliperidone palmitate
- Volunteers
- 748 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual
The study examines the effect of cognitive training on cognitive functioning and everyday competencies of patients with schizophrenia.
- Trial name
- NEUROCOM (NCT00472862)
- Testing
- Cognitive training
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Neurocom
Schizophrenia
Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-
The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.
- Trial name
- NCT00392197
- Testing
- Aripiprazole
- Where
- 5 sites in Japan
- Volunteers
- 111 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Psychotic Disorders
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
This is a study in people between 16 and 30 years of age who have a specific type of mental illness called attenuated psychosis syndrome (APS).
- Trial name
- NCT03230097
- Testing
- BI 409306
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia
The research aims to investigate the relationship between self-control ability and blood glucose level in schizophrenic patients.
- Trial name
- NCT01563016
- Testing
- glucose drink
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.